Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ctnm · stock forecast · 3 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$16.00
Consensus
$16.00
+39.9% upside
Low
$16.00
Median: $16 · Last Close: $11.44
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $10.86 | ↓ 5.00% |
1-day model range: $10.79–$10.94. Peak: $10.94 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $6 | -47.5% |
| 2028 | $4 | -61.2% |
| 2029 | $4 | -66.8% |
| 2030 | $4 | -69.4% |
| 2031 | — | -70.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CTNM · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-14 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2026-03-06 | Baird | Maintains | Outperform→Outperform |
| 2026-01-08 | Morgan Stanley | Downgrade ↓ | Overweight→Equal Weight |
| 2025-11-24 | Baird | Maintains | Outperform→Outperform |
| 2025-11-21 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-08-18 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2025-05-19 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2025-05-15 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-03-07 | Baird | Maintains | Outperform→Outperform |
| 2025-01-09 | RBC Capital | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock. Of the recent 12 rating actions, 0 were upgrades and 1 were downgrades. 3 analysts currently cover CTNM.
Analyst Recommendation Trends
CTNM analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$7M
↑ 100.5% YoY
Revenue Next Year
$2M
↓ 68.0% YoY
EPS This Year
$-1.65
EPS Next Year
$-1.81
↑ 10.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast CTNM EPS of $-1.65 for the current fiscal year, based on estimates from 5 analysts. The CTNM revenue forecast is $7M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CTNM stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CTNM price target is $16.00 (+39.9% upside), with an analyst consensus of Buy.
The CTNM short-term stock prediction for tomorrow is $10.86 (-5.00%). The CTNM stock price prediction for 2027 estimates an average of $6. The CTNM stock prediction for 2030 projects a range of $3–$4.
Contineum Therapeutics, Inc. Class A Common Stock trades on NASDAQ under the ticker CTNM. The CTNM stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
CTNM forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month CTNM price target is $16.00, with a high forecast of $16.00 and a low of $16.00. The median price target is shown in the chart above when available. This implies +39.9% potential upside from the current price of $11.44.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.